1. Pink Sheet

US FDA Calls For Clinical Trial Diversity Plan ‘As Soon As Practicable’ In Product Development

 
• By Bridget Silverman

Draft guidance outlines Race and Diversity Plan that would reify some of FDA’s efforts to increase racial and ethnic diversity in clinical trials with a mechanism that is applicable from IND through approval.

Diversity
FDA provides guidance on improving diversity in clinical trial enrollment • Source: Alamy

Drug sponsors should submit a “Race and Ethnicity Diversity Plan” early in clinical development that can be revisited and revised throughout a drug’s regulatory life to enhance diversity in clinical trials, the US Food and Drug Administration advises.

The agency describes what sponsors should include in the plan in a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D